A Study of Abatacept in Japanese Patients With Active Rheumatoid Arthritis While Receiving Methotrexate
NCT ID: NCT00345748
Last Updated: 2011-04-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
194 participants
INTERVENTIONAL
2006-06-30
2007-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Abatacept Post-marketing Clinical Study in Japan
NCT01758198
Efficacy, Pharmacokinetics, Safety, and Immunogenicity Study of Abatacept Administered Subcutaneously to Treat Rheumatoid Arthritis in Japanese Patients
NCT01001832
A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
NCT00048568
Abatacept With Methotrexate- Phase IIB
NCT00162266
A Phase III Study of Abatacept in Japanese Subjects With Rheumatoid Arthritis
NCT00484289
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Abatacept 2 mg/kg
Abatacept
Injection, IV Infusion, Day 1, 15, 29 and every 28 days for 24 weeks
Abatacept 10 mg/kg
Abatacept
Injection, IV Infusion, Day 1, 15, 29 and every 28 days for 24 weeks
Placebo
Placebo
Injectio, IV Infusion, Day 1, 15, 29 and every 28 days for 24 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Abatacept
Injection, IV Infusion, Day 1, 15, 29 and every 28 days for 24 weeks
Placebo
Injectio, IV Infusion, Day 1, 15, 29 and every 28 days for 24 weeks
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bristol-Myers Squibb
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Local Institution
Nagoya, Aichi-ken, Japan
Local Institution
Nagoya, Aichi-ken, Japan
Local Institution
Goshogawara-Shi, Aomori, Japan
Local Institution
Chiba, Chiba, Japan
Local Institution
Fukui-shi, Fukui, Japan
Local Institution
Fukui-shi, Fukui, Japan
Local Institution
Fukuoka, Fukuoka, Japan
Local Institution
Fukuoka, Fukuoka, Japan
Local Institution
Kitakyushu-Shi, Fukuoka, Japan
Local Institution
Higashi-Hiroshima-Shi, Hiroshima, Japan
Local Institution
Sapporo, Hokkaido, Japan
Local Institution
Sapporo, Hokkaido, Japan
Local Institution
Sapporo, Hokkaido, Japan
Local Institution
Kanzaki-Gun, Hyōgo, Japan
Local Institution
Kato-Gun, Hyōgo, Japan
Local Institution
Hitachi-Shi, Ibaraki, Japan
Local Institution
Tsukuba, Ibaraki, Japan
Local Institution
Sagamihara-Shi, Kanagawa, Japan
Local Institution
Sendai, Miyagi, Japan
Local Institution
Sendai, Miyagi, Japan
Local Institution
Sendai, Miyagi, Japan
Local Institution
Nagano, Nagano, Japan
Local Institution
Tsukubo-Gun, Okayama-ken, Japan
Local Institution
Kawachinagano-Shi, Osaka, Japan
Local Institution
Ureshino-Shi, Saga-ken, Japan
Local Institution
Iruma-Gun, Saitama, Japan
Local Institution
Kawagoe-Shi, Saitama, Japan
Local Institution
Kitamoto-Shi, Saitama, Japan
Local Institution
Hamamatsu, Shizuoka, Japan
Local Institution
Kawachigun, Tochigi, Japan
Local Institution
Tochigi, Tochigi, Japan
Local Institution
Arakawa-Ku, Tokyo, Japan
Local Institution
Bunkyo-Ku, Tokyo, Japan
Local Institution
Bunkyo-Ku, Tokyo, Japan
Local Institution
Setagaya-Ku, Tokyo, Japan
Local Institution
Shinjuku-Ku, Tokyo, Japan
Local Institution
Takaoka-Shi, Toyama, Japan
Local Institution
Chiba, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IM101-071
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.